PROSTATE SCREENING QUALITY OF LIFE REDUCTIONS
This article was originally published in The Gray Sheet
Executive Summary
PROSTATE SCREENING QUALITY OF LIFE REDUCTIONS outweigh the 1-2 day increases in life expectancy realized through screening, Murray Krahn, MD, University of Toronto, et al., conclude in a study published in the Sept. 14 issue of the Journal of the American Medical Association. Using information obtained from existing databases, the authors say their "analysis shows that screening may marginally reduce prostatic cancer mortality for men between the ages of 50 and 70 years, but it suggests that the benefits of reduced prostatic cancer mortality are more than offset by the morbidity of prostatic cancer treatment."
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.